Summary
Cholesterol-lowering interventions are employed widely and safely to reduce risk of cardiovascular disease. Cholesterol may have complex and opposing effects on immunity. We lowered serum cholesterol to clinically relevant levels in mice and evaluated the final adaptive immune response. Mice treated with oral ezetimibe exhibited enhanced antitumor immunity against syngeneic cancers in a CD8+ lymphocyte-dependent manner, produced immunity that was transferrable through lymphocytes, and enhanced central CD8+ T cell memory. In both mice and patients undergoing prostatectomy, lowering serum cholesterol inhibited mTORC2 signaling in lymphocytes and increased infiltration of CD8+ lymphocytes into prostate tumors. Lymphocyte-specific mTORC2 knockout mice demonstrated enhanced CD8+ lymphocyte function and antitumor capacity. In a prospective clinical trial, cholesterol-lowering intervention prior to prostatectomy decreased the proliferation of normal prostate and low-grade adenocarcinomas. Here, we show that lowering serum cholesterol may be an effective strategy to decrease signaling through mTORC2 and enhance antitumor CD8+ T cell memory.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT02534376
Funding Statement
This work was supported by grants from the Samuel Oschin Comprehensive Cancer Center, Winnick Family Foundation, Homer and Gloria Harvey Family Endowed Chair, Teshinsky Family Foundation and the National Institutes of Health (R01CA182438). The clinical trial reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under the Award Number UG1CA189823 to the Alliance for Clinical Trials in Oncology NCORP Research Base (Jan C. Buckner, M.D., contact PI). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
A prospective, window-of-opportunity trial was previously conducted (ClinicaltTrials.gov identifier: NCT02534376) and provided tissue and serum. Patients with clinically significant prostate cancer scheduled to undergo prostatectomy provided written consent and were enrolled in Pro40945, which is a clinical trial that received ethics approval from the Cedars Sinai Medical Centers Institutional Review Board (Los Angeles, CA).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Yanping Wang, Cedars-Sinai Medical Center, 8635 W. Third Street, Suite 1070, Los Angeles, CA 90048, Yanping.Wang{at}cshs.org
Sungyong You, Cedars-Sinai Medical Center, 8635 W. Third Street, Suite 1070, Los Angeles, CA 90048, Sungyong.You{at}cshs.org
Shengchen Su, Cedars-Sinai Medical Center, 8635 W. Third Street, Suite 1070, Los Angeles, CA 90048, Shengchen.Su{at}cshs.org
Austin Yeon, Cedars-Sinai Medical Center 8635 W. Third Street, Suite 1070, Los Angeles, CA 90048, Austin.Yeon{at}cshs.org
Eric M. Lo, Baylor College of Medicine, Houston, TX, Eric.Lo{at}bcm.edu
Sungjin Kim, Cedars-Sinai Medical Center, 8635 W. Third Street, Suite 1070, Los Angeles, CA 90048, Sungjin.Kim{at}cshs.org
James L. Mohler, Roswell Park Cancer Institute, 665 Elm St, Buffalo, NY 14203, James.Mohler{at}RoswellPark.org
Michael R. Freeman, Division of Cancer Biology and Therapeutics, Departments of Surgery & Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, California 90048, Michael.Freeman{at}cshs.org
Hyung L. Kim, Division of Urology, Departments of Surgery, Cedars-Sinai Medical Center, Los Angeles, California 90048
Summary: Findings offer preclinical and early clinical evidence that lowering serum cholesterol enhances antitumor immunity.
Data Availability
The RNAseq data is available at GEO (accession number GSE159529.
